[Expert consensus on urate-lowering therapy for high-risk hyperuricemia (2025 edition)].

Hyperuricemia (HUA) is prevalent in China with an increasing prevalence and a trend towards the youth. Long-term HUA can lead to gout, kidney stones and renal impairment, and also is associated with the development and progression of other organ damage, including cardiovascular diseases, metabolic disorders, and neurological conditions, etc. In order to identify high-risk individuals for HUA-related damage and establish standardized management strategies, to identify which HUA patients may be recommended for drug-related urate-lowering therapy (ULT) and propose detailed treatment regimens (such as optimal timing, drug choice and treatment targets, etc.), the Chinese Rheumatology Association and the Committee for Rheumatologists and Immunologists of Chinese Primary Health Care Foundation organized domestic experts to develop the Expert Consensus on Urate-lowering Therapy for High-Risk Hyperuricemia (2025 edition). This consensus systematically summarizes the latest domestic and international evidence, incorporates China-specific patient conditions and expert opinions, defines high-risk hyperuricemia (HrHUA) as well as 18 ULT relevant clinical issues, and provides detailed recommendations to standardize diagnosis and treatment practices, ultimately improving patient outcomes.